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ARTICLE OPEN
An unsuspected role for organic cation transporter 3 in the
actions of amphetamine
Felix P. Mayer1, Diethart Schmid1, W. Anthony Owens2, Georgianna G. Gould 2, Mia Apuschkin3, Oliver Kudlacek1, Isabella Salzer1,
Stefan Boehm1, Peter Chiba 4, Piper H. Williams5, Hsiao-Huei Wu5, Ulrik Gether 3, Wouter Koek6,7, Lynette C. Daws2,7 and
Harald H. Sitte 1,8
Amphetamine abuse is a major public health concern for which there is currently no effective treatment. To develop effective
treatments, the mechanisms by which amphetamine produces its abuse-related effects need to be fully understood. It is well
known that amphetamine exerts its actions by targeting high-afﬁnity transporters for monoamines, in particular the cocaine-
sensitive dopamine transporter. Organic cation transporter 3 (OCT3) has recently been found to play an important role in regulating
monoamine signaling. However, whether OCT3 contributes to the actions of amphetamine is unclear. We found that OCT3 is
expressed in dopamine neurons. Then, applying a combination of in vivo, ex vivo, and in vitro approaches, we revealed that a
substantial component of amphetamine’s actions is OCT3-dependent and cocaine insensitive. Our ﬁndings support OCT3 as a new
player in the actions of amphetamine and encourage investigation of this transporter as a potential new target for the treatment of
psychostimulant abuse.
Neuropsychopharmacology (2018) 43:2408–2417; https://doi.org/10.1038/s41386-018-0053-5
INTRODUCTION
Amphetamine-type drugs are among the most commonly
abused in the world, afﬂicting an estimated 56 million people
[1], creating a major public health burden, and underscoring a
vital need to ﬁnd effective treatments. Currently there are no
medications to treat psychostimulant addiction, including addic-
tion to amphetamine [2]. To develop effective treatments, the
mechanisms by which these stimulants produce their abuse-
related effects need to be fully understood. It is well known that
amphetamine, as well as many other stimulants, interact with
high-afﬁnity transporters for monoamine neurotransmitters, the
dopamine (DA), norepinephrine (NE), and serotonin (5-HT)
transporters (DAT, NET, and SERT, respectively) [3]. These
transporters are thought to be the main players regulating
clearance of these monoamines from extracellular ﬂuid. However,
a rapidly growing literature supports a prominent role for organic
cation transporter 3 (OCT3) in the regulation of monoaminergic
neurotransmission [4–13].
OCT3 is a low-afﬁnity (“uptake-2”) transporter with a high
capacity to non-selectively transport monoamines [14]. It is also
a bidirectional transporter, and there is evidence that OCT3 may
play an important role in neurotransmitter efﬂux [5]. Moreover,
gene variants of OCT3 have been linked to methamphetamine
abuse [15]. OCT3 is distributed widely in brain, and is richly
expressed in brain regions important in the rewarding effects
of amphetamine, including striatum and nucleus accumbens
[6, 12]. Taken together, these ﬁndings raise the possibility that
OCT3 may be important for the actions of amphetamine-type
psychostimulants that cause release of monoamines. However,
whether OCT3 contributes to the actions of amphetamine is
unclear.
It is well documented that amphetamine is a substrate for DAT,
and therefore, a competitive inhibitor of DA uptake. Once inside
the nerve terminal, amphetamine acts to increase cytosolic
concentrations of DA via its activity at the vesicular monoamine
transporter 2 (VMAT2), leading to reverse transport (or efﬂux) of
DA into the extracellular space via DAT [16, 17]. A previous study
reported that amphetamine is not a substrate for OCT3 and,
therefore, concluded that amphetamine is unlikely to inhibit
monoamine uptake via OCT3 [18]. However, it is conceivable that
amphetamine, once gaining access to the intracellular compartment
via its transport through DAT (or other mechanism(s)), may
promote neurotransmitter efﬂux via OCT3. To our knowledge, no
studies have investigated this possibility. Here we report the novel
ﬁnding that a substantial component of amphetamine-evoked
substrate release (i.e., DA and 1-methyl-4-phenylpyridinium
(MPP+)) is OCT3-dependent and cocaine (a blocker of DAT,
NET, and SERT) insensitive. Our ﬁndings encourage further
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investigation of OCT3 in the actions of amphetamine and as a
potential target for the development of novel therapeutics to treat
amphetamine addiction.
MATERIALS AND METHODS
Wild-type mice (OCT3+/+), or OCT3 knockout (KO, OCT3−/−)
mice, bred on a C57BL/6 background (originally developed by
Zwart et al. 2001 [19]), were obtained from an in house colony at
the University of Texas Health Science Center at San Antonio
(UTHSCSA). Transgenic Dat1-eGFP mice were generated by the
GENSAT project [20], and maintained at the University of
Copenhagen. All procedures were conducted in accordance with
the National Institute of Health Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research Council 1996),
and with the approval of the Institutional Animal Care and Use
Committee, UTHSCSA, and the Danish Animal Experimentation
Inspectorate (permission number: 2012-15-2934-00279). Details of
age, gender, housing, and procedures using animals can be found
in the Supplementary information.
OCT3 was identiﬁed in DAergic neurons using multiplex
ﬂuorescence in situ hybridization (FISH) in brain slices containing
ventral tegmental area (VTA), or in DA neurons isolated
from midbrain of Dat1-eGFP mice according to established
methods [21, 22]. Amphetamine-stimulated locomotor activity was
recorded using automated equipment. High-speed chronoampero-
metry was used to measure amphetamine-stimulated DA
release in vivo, according to established methods [23].
Quantitative autoradiography of [3H]WIN35428 binding was used
to assess DAT expression in OCT3+/+ and OCT3−/− mice.
Radiotracer ﬂux assays using [3H]MPP+ were carried out in rat
cultured superior cervical ganglion cells (SCGs). The ﬂuorescent
substrate 4-(4-dimethylamino-styryl)-N-methylpyridinium (ASP+) or
[3H]MPP+ were used to measure substrate uptake and efﬂux in
human embryonic kidney (HEK293) cells expressing either human
OCT3 tagged with yellow ﬂuorescent protein (YFPhOCT3), hVMAT2,
or hNET, according to established methods [24, 25]. Detailed
descriptions of all methods can be found in the Supplementary
information.
RESULTS
OCT3 is expressed in DAT- and VMAT2-positive neurons
Since the primary action of amphetamine results in robust DA
release, we ﬁrst wanted to conﬁrm that OCT3 is expressed in
dopaminergic neurons.
To this end, we used a previously established method for
isolation of midbrain DA neurons by ﬂuorescence-activated cell
sorting (FACS) on the basis of enhanced green ﬂuorescent
protein (eGFP) expression in dopaminergic neurons in transgenic
Dat1-eGFP mice [21]. Analysis by qPCR clearly detected
OCT3 mRNA in DA positive (eGFP+) neurons although mRNA
was not enriched in these neurons compared with eGFP
negative (eGFP−) cells (Fig. 1a–c). Additionally, as revealed
by RNAscope, OCT3 was detected in VMAT2-positive cells
in VTA (Fig. 1d–f). Interestingly, both approaches showed that
OCT3 was also observed in cells that were not DA- (Fig. 1b, c) or
VMAT2-positive (Fig. 1d–f), indicating the presence of OCT3
on neurons other than those positive for DA or VMAT, as well as
non-neuronal expression. This ﬁnding is consistent with existing
literature reporting both neuronal and glial expression
of OCT3 [4, 9, 12, 26–28].
Ability of decynium-22 to inhibit amphetamine-induced
hyperactivity depends on availability of OCT3
To determine if inhibition of OCT3 has consequences for the
behaving animal, we investigated the effect of the non-selective
OCT inhibitor, decynium-22 (D22), on amphetamine-induced
locomotion in OCT3+/+ and OCT3–/– mice. Though D22 inhibits
all OCT isoforms (OCT1, OCT2, OCT3), as well as the plasma
membrane monoamine transporter (PMAT), its use for in vivo
studies is preferential to the potent OCT3 blocker, corticosterone,
which also has actions at glucocorticoid receptors [7]. Importantly,
D22 does not appear to have any appreciable afﬁnity for the
high-afﬁnity monoamine transporters (DAT, NET, and SERT)
(unpublished data, manuscript in submission). Thus, the combined
use of D22 with OCT3−/− mice affords a useful model to study
OCT3-dependent actions of D22 and the consequences for
behavioral response to amphetamine. Consistent with existing
literature [12], there was no difference in basal locomotor activity
between OCT3 genotypes under vehicle injection conditions.
Maximal hyperactivity occurred after administration of 3.2 mg/kg
amphetamine in OCT3+/+ and OCT3−/− mice (Supplementary
Figure S1). Strikingly, however, pre-treatment with D22 decreased
amphetamine-induced locomotion in OCT3+/+ mice but not in
OCT3−/− mice (Fig. 2a). These effects of D22, which were
observed during the ﬁrst 30 min of the session, were also apparent
during the entire session (Supplementary Figure S1) and
suggest that OCT3 does indeed contribute to the actions of
amphetamine.
Ability of D22 to inhibit amphetamine-evoked DA efﬂux is
dependent on OCT3 in vivo
Based on the ability of D22 to inhibit amphetamine-induced
hyperlocomotion in OCT3+/+mice, but not in OCT3−/−mice, we
next investigated if pharmacological inhibition or genetic ablation
of OCT3 would impinge upon the ability of amphetamine to evoke
DA release in vivo. To this end, we used high-speed chronoam-
perometry to measure amphetamine-evoked DA release in
striatum of OCT3+/+ and OCT3−/− mice (Fig. 2b, Supplementary
Discussion and Tables S1–3). The striatum is not only rich in DAT,
but also expresses OCT3 [6], and is important in the locomotor
effects of amphetamine. There was no signiﬁcant difference in
amphetamine-evoked DA release between genotypes under
control conditions, consistent with the lack of difference in
amphetamine-induced hyperlocomotion. In addition, we found
that expression of DAT (the primary target for amphetamine) in
striatum, did not differ between genotypes (Supplementary
Table S4).
Prior to testing drugs in vivo, we ﬁrst conﬁrmed in vitro that
neither amphetamine, cocaine, D22, or their combination
produced an electrochemical signal themselves, nor interfered
with the recording properties of the electrode at the concentra-
tions used here (see [13, 29]). As expected, amphetamine-evoked
DA release in OCT3+/+ mice was inhibited (~23%) by pre-
treatment with the DAT blocker, cocaine. However, D22 also
inhibited (~41%) amphetamine-evoked DA release in OCT3+/+
mice, and when given together with cocaine produced greater
inhibition (~58%) of amphetamine-evoked DA release than either
drug given alone (Fig. 2b, c, Supplementary Tables S2, 3),
suggesting that these drugs are acting at different sites. As for
OCT3+/+ mice, cocaine inhibited (58%) amphetamine-evoked DA
release in OCT3−/− mice. However, in contrast to OCT3+/+ mice,
D22 had no effect on amphetamine-evoked DA release in
OCT3−/− mice, nor did it enhance the effect of cocaine to inhibit
(~60%) amphetamine-evoked DA release (Fig. 2b, c). Taken
together, our in vivo data strongly support the idea that
amphetamine-evoked DA release occurs via both DAT and
OCT3.
It is worth noting the relatively high degree of variance
associated with most signal parameters in our chronoampero-
metric measurements (Fig. 2b). This is neither surprising nor
unusual. A primary factor contributing to this variance is the
excellent spatial resolution afforded by these small carbon ﬁber
recording electrodes. Thus, the extracellular milieu surrounding
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the electrode (e.g., density of transporters) may differ signiﬁ-
cantly from experiment to experiment (i.e., from mouse to
mouse), regardless of how consistent stereotaxic placement may
be. Similarly, factors affecting diffusion through extracellular
ﬂuid (such as tortuosity and volume fraction) may also
contribute to variance in release and clearance kinetics from
one experiment to the next (compare representative pre-drug
DA signals in Fig. 3a). Thus, our ability to detect marked effects
of D22 and cocaine on amphetamine-evoked DA release in the
face of this inherent “noise” underscores the magnitude and
robustness of these drug effects on amphetamine-evoked DA
release.
Full inhibition of amphetamine-induced efﬂux of [3H]MPP+ in SCG
cells ex vivo is only achieved when D22 is co-administered with a
maximally effective concentration of cocaine
To further validate our in vivo ﬁndings, we turned to an ex vivo
preparation of cultured rat SCG cells. SCGs are enriched with
neuronal OCT3 and NET, but lack OCT1 or OCT2 [26]. By blocking
NET with cocaine, this preparation provides a readily accessible
ex vivo system to aid in deciphering the contribution of OCT3 to
actions of amphetamine in neurons. SCGs were pre-loaded with
[3H]MPP+, superfused with buffer, and exposed to amphetamine
(10 µM), which resulted in a marked increase of substrate release
(Fig. 3a). The addition of cocaine at a concentration sufﬁcient to
block amphetamine-induced efﬂux via NET (20 µM; Fig. 3b, c)
failed to fully abolish amphetamine-evoked [3H]MPP+ release
from SCGs, reducing the effect of amphetamine by only 30%
(Fig. 3a). The cocaine-insensitive component of amphetamine-
induced [3H]MPP+ efﬂux in SCGs was inhibited by D22, in a
concentration-dependent manner (Fig. 3a). In the presence of
cocaine (20 µM) and D22 (10 µM), amphetamine-evoked [3H]MPP+
efﬂux was completely blocked. Analysis by two-way ANOVA
(treatment × time) revealed that drug treatments signiﬁcantly
affected the fractional release of [3H]MPP+ (F4,38= 30.63, P <
0.0001). To ensure that 20 µM cocaine was fully blocking NET in
SCGs, we increased the concentration of cocaine to 100 µM. As
shown in Fig. 3b, the higher concentration of cocaine also
inhibited amphetamine-evoked [3H]MPP+ efﬂux (two-way ANOVA,
treatment × time, F3,29= 17.08, P < 0.0001), but not to a greater
Fig. 1 Identiﬁcation of OCT3 in dopaminergic neurons and VMAT2-positive cells. a Fluorescence activated cell sorting (FACS) of a single cell
solution of transgenic Dat1-eGFP midbrain cells, with the relative intensity of ﬂuorescence at 513/26 nm against 576/21 nm after excitation at
488 nm. Inset shows similar FACS of a single-cell solution from a wild-type littermate. b Relative expression of DA and non-DA markers in the
eGFP positive (eGFP+) sorted population compared with the eGFP negative (eGFP−) sorted population after normalization to housekeeping
genes (ΔΔCq), dopamine transporter (Dat), tyrosine hydroxylase (Th), vesicular monoamine transporter 2 (Vmat2), glutamate decarboxylase 1
(Gad1), and nuclear receptor related 1 protein (Nurr1). Data are represented as mean obtained from three experiments. Data reveal enrichment
of DA markers (Dat, Th, Vmat2, Nurr1) and a decrease in expression of the non-DA marker (Gad1) in the eGFP+ population. Organic cation
transporter 3 (Oct3) was expressed in equivalent amounts in eGFP+ and eGFP− populations, as highlighted further in c, showing the
expression of Oct3 relative to a ﬁxed detection limit with Cq= 35 set to 1. Oct3 is detected in both populations (n= 3, dashed line= detection
limit) with no difference in expression between the two populations (two-tailed Mann–Whitney test, p= 0.9, n.s. not signiﬁcant). Importantly,
the Oct3 primer pair was designed to be intron-spanning, eliminating the possibility of ampliﬁcation of genomic DNA, which was also evident
in data that showed no signal in the no-RT samples. Melt curve analysis of the product showed ampliﬁcation of a speciﬁc target (data not
shown), and primer blast analysis of the Oct3 primers showed only one product for the primer pair, that product being Oct3. d–f Expression of
Oct3 in Vmat2-positive neurons in VTA. Multiplex ﬂuorescent in situ hybridization (FISH) using RNAscope probes directed against Vmat2
(green) and Oct3 (red) performed on adult fresh frozen sections. In VTA, approximately 50% of Vmat2-positive cells were also positive for Oct3.
Arrow points to a cell expressing both Oct3 and Vmat2. Arrowhead points to a cell expressing Vmat2 only. Blue: DAPI
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extent than 20 µM, suggesting that 20 µM of cocaine is sufﬁcient
to fully block NET in SCGs. In line with this observation, 20 µM
cocaine signiﬁcantly inhibited amphetamine-induced [3H]MPP+
efﬂux in HEK293 cells stably expressing hNET (two-way ANOVA,
treatment × time, F1,25= 10.76, P < 0.01) (Fig. 3c).
It is not known if SCGs express PMAT. Therefore, to conﬁrm that the
effect of D22 to inhibit [3H]MPP+ release in SCGs is OCT3 dependent,
we repeated this experiment using corticosterone in combination
with the highly selective NET blocker desipramine. Corticosterone is a
blocker of OCT3 [14] but not PMAT [30], and therefore is a useful tool
to parse out the contribution of these transporters to substrate
release. Like D22, corticosterone inhibited amphetamine-induced [3H]
MPP+ release in the presence of a NET-inhibitor in SCGs, suggesting
that the effect of D22 is unlikely to be PMAT dependent (Fig. 3d).
Thus, consistent with our in vivo studies, ex vivo studies support a role
for OCT3 in the actions of amphetamine.
Amphetamine and cocaine are not inhibitors of OCT3-mediated
transport of 4-(4-dimethylamino-styryl)-N-methylpyridinium
(ASP+) in YFPhOCT3-expressing HEK293 cells
Results so far implicate a role for OCT3 in the mechanism
of action of amphetamine. However, because D22 is not
selective for OCT3 over other OCT isoforms and PMAT, and
because our in vivo studies do not afford deeper mechanistic
insight into how the actions of amphetamine may be OCT3
dependent, we turned to a cell-based system to interrogate
a role for OCT3 in the actions of amphetamine. To do so,
we investigated OCT3-mediated transport of the ﬂuorescent
compound ASP+ into HEK293 cells stably expressing human
OCT3 tagged with yellow ﬂuorescent protein (YFPhOCT3) (Fig. 4a).
ASP+ affords the temporal resolution to monitor instantaneous
effects of test drugs on OCT3-mediated transport, providing a
direct readout of substrate transport that is driven by the
electrochemical gradient. ASP+ uptake was ~4.5-fold greater in
YFPhOCT3 cells compared with parental HEK293 cells (Fig. 4b).
Inversion of the electrochemical gradient for ASP+ (upon
cessation of microsuperfusion of ASP+) instantly resulted in
ASP+ release from YFPhOCT3 cells (Fig. 4b). Co-application of
the non-ﬂuorescent OCT3 substrate MPP+ competitively inhibited
ASP+ uptake into YFPhOCT3 cells in a concentration-dependent
manner (Fig. 4c).
It is well known that amphetamine, a substrate for DAT, and
cocaine, a DAT blocker, potently inhibit uptake of substrates such
as ASP+ and MPP+ via high-afﬁnity monoamine transporters [3]. In
contrast, neither amphetamine nor cocaine had any impact
on OCT3-mediated uptake of ASP+ (Fig. 4d) and [3H]MPP+
(Supplementary Figure 2A), respectively, at concentrations below
40 µM. These data conﬁrm that there is no direct action of
amphetamine or cocaine on OCT3 at concentrations that have
been reported to be behaviorally relevant [31–33]. In contrast, the
OCT3 inhibitor, corticosterone, blocked uptake of ASP+ into
YFPhOCT3 cells (Fig. 4d). Similar results were obtained with
D22, which, like corticosterone, inhibited uptake of [3H]MPP+
(Supplementary Figure 2B). With both substances, half maximal
inhibition was achieved with concentrations in the low micro-
molar range.
These results suggest that our in vivo and ex vivo ﬁndings are
unlikely attributable to a direct action of amphetamine or cocaine
Fig. 2 D22 attenuates amphetamine-evoked locomotor activity and DA release in OCT3+/+mice, but not in OCT3−/−mice. a Amphetamine
increased locomotion during the 30-min period immediately after an intraperitoneal (i.p.) injection of 3.2 mg/kg, and did so similarly in OCT3
+/+ mice (ﬁlled circles) and in OCT3−/− mice (open circles). Pre-treatment with D22 (0.1 mg/kg) decreased this effect of amphetamine in
OCT3+/+ mice (ﬁlled squares), but not in OCT3−/− mice (open squares). Results, shown as mean ± standard error of the mean (S.E.M, n=
7–8), were analyzed by two-factor ANOVA followed by multiple comparisons (Sidak’s test): *p < 0.05 compared with all other groups treated
with 3.2 mg/kg amphetamine; #p < 0.05 compared with saline-treated groups. Note that D22 did not signiﬁcantly reduce locomotor activity in
OCT3+/+ and OCT3−/−mice treated with saline instead of amphetamine (p= 0.87 and 0.99, respectively). b, c Intra-striatal pressure ejection
of amphetamine (15 pmol) at 45 min intervals elicited reproducible oxidation currents that were identiﬁed as predominantly DA in nature,
based on the ratio of reduction and oxidation currents produced (i.e., greater than 0.5; see Supplementary Table S3). Having established the
reproducibility of amphetamine-evoked DA release in dorsal striatum of anesthetized mice, subsequent experiments followed the protocol of
applying amphetamine (15 pmol), and 45min later either aCSF vehicle, cocaine (15 pmol), or D22 (1 pmol), either alone or in combination,
followed 15min later by another application of amphetamine (15 pmol). b Representative oxidation signals produced by amphetamine-
evoked DA release in striatum. Black traces are amphetamine-evoked DA release prior to aCSF or test drug; blue traces are amphetamine-
evoked DA release 15 min following test drug, and are superimposed on pre-test drug traces for ease of comparison (see Supplementary
Tables S1-3). c Time line showing that effects of test drugs and aCSF on amphetamine-evoked DA release were compared to the last release
event that occurred prior to their administration. Summary data are shown as mean and 95 % conﬁdence intervals (95% CL). Sample sizes for
each group are shown below each column and ranged from 7 to 14. Data were analyzed by two-factor ANOVA followed by multiple
comparisons (uncorrected Fisher’s LSD); *p < 0.05, **p < 0.001, ***p < 0.0001 vs. genotype-matched aCSF group; ^p < 0.05 vs. genotype-
matched D22 group. In OCT3+/+mice, there was no signiﬁcant difference between D22+aCSF and D22+cocaine, but the difference between
aCSF+cocaine and D22+cocaine approached signiﬁcance (p= 0.058). Note that there was no signiﬁcant difference between genotypes in
response to cocaine (p = 0.09)
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at OCT3, as either a substrate or blocker. Importantly, if
amphetamine is not a substrate for OCT3 (as our cell-based data,
and others [18] show), amphetamine must gain entry to cells via
an OCT3-independent mechanism.
Co-transfection of YFPhOCT3 cells with hVMAT2 provides
evidence that amphetamine gains access to the intracellular
compartment via an OCT3-independent mechanism
Given our data showing that amphetamine does not gain entry to
the intracellular compartment of YFPhOCT3 cells via OCT3, we
wanted to determine that amphetamine can indeed gain entry to
the cell. A prerequisite for amphetamine to induce reverse
transport via the plasmalemmal transporters, DAT, NET, and SERT,
is access to cytosolic monoamines. Converging lines of evidence
suggest that amphetamine interacts with VMAT2, disrupting its
function, and causing redistribution of monoamines from vesicles
into the cytosol [17]. To determine if manipulations of VMAT2
function and concomitant elevations of cytosolic substrate result
in outwardly directed transport via OCT3, we transfected
YFPhOCT3 cells with hVMAT2. Cells were pre-loaded with [3H]
MPP+, transferred into small chambers, and superfused. Addition
of amphetamine (10 or 30 µM) signiﬁcantly increased efﬂux of [3H]
MPP+ compared to the untreated control condition (two-way
ANOVA, treatment × time, F2,27= 16.31, P < 0.0001). These data
suggest that amphetamine is indeed able to gain access
to the intracellular compartment of YFPhOCT3 cells, where it can
act at hVMAT2 to increase cytosolic [3H]MPP+, resulting in
gradient-driven reverse transport of [3H]MPP+ from the cells via
OCT3 (Fig. 4e).
DISCUSSION
The major ﬁnding of the present study is that OCT3 is a previously
unsuspected player in the complex mechanisms of action of
amphetamine. This conclusion is based on our ﬁndings that
(1) D22, the non-selective OCT/PMAT blocker, inhibited
amphetamine-induced locomotor activity and amphetamine-
induced DA release in vivo in wild-type mice, but not in
OCT3−/− mice; (2) in ex vivo SCG preparations (rich in OCT3
and NET), a concentration of cocaine that fully blocks [3H]MPP+
efﬂux via NET, only fully blocked efﬂux in SCGs in the presence of
D22. Furthermore, corticosterone augmented the inhibitory
Fig. 3 Amphetamine-induced efﬂux via OCT3 in an ex vivo system. a AMPH (10 µM) triggered efﬂux of pre-loaded [3H]MPP+ starting at t= 0
min from cultured rat superior cervical ganglia (SCG) cells in the absence or presence of cocaine (COC, 20 µM) or cocaine and D22 (COC 20 µM
plus 0.1 µM D22, 1 µM D22, 10 µM D22, respectively). Addition of substances is indicated by black bars; Data are mean ± S.E.M., n= 9–12
independent observations per condition, *P < 0.05, (Bonferroni’s) compared to the control trace. b AMPH (10 µM) triggered efﬂux of [3H]MPP+
from SCGs (as in a) in the absence or presence of cocaine (20 or 100 µM, respectively) or cocaine (100 µM) and D22 (10 µM); * denotes statistical
difference of COC 20 µM vs. the control trace; # denotes signiﬁcance of COC 100 µM compared to the control trace and Φ indicates difference
of COC 100 µM+10 µM D22 vs. all other groups (*, #, Φ, P < 0.05, Bonferroni’s). c AMPH-induced efﬂux of pre-loaded [3H]MPP+ starting at t= 0
min from HEK293 cells stably expressing human NET in the absence or presence of cocaine (COC; 20 µM). Black bars indicate addition of
substances (*P < 0.05 (Bonferroni’s)). d AMPH (10 µM)-induced efﬂux of pre-loaded [3H]MPP+ from cultured SCGs (as in a) in the presence of
desipramine (DES, 1 µM) and/or desipramine and corticosterone (CORT, 30 µM and 100 µM). For comparison, area under the curve (AUC) of the
last ﬁve fractions in the presence of AMPH was calculated for each observation and analyzed by Kruskal–Wallis, followed by Dunn’s (*P < 0.05)
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effects of the highly selective NET-inhibitor desipramine on
amphetamine-induced release in SCGs; (3) as shown by our
studies using YFPhOCT3 cells, while amphetamine is not a
substrate for OCT3 (at least at behaviorally relevant concentra-
tions), it can gain access to the intracellular compartment
(putatively via diffusion across the plasma membrane) to interact
with VMAT2 and subsequently promote efﬂux of substrate via
OCT3. Figure 5 illustrates a working model of the OCT3- and
DAT-dependent actions of amphetamine, based on these ﬁndings.
First it was important to verify if OCT3 is present on monoamine
neurons in the central nervous system. Whether OCT3 resides on
monoaminergic neurons remains under debate with evidence
reported both for [9, 12, 26, 28, 34] and against [4, 27], at least with
regard to DA neurons. Our cellular localization studies revealed
OCT3 mRNA in isolated DAergic neurons (eGFP+). In addition,
anatomically resolved RNAscope studies identiﬁed OCT3 in
VMAT2-positive neurons in VTA. These ﬁndings are in line with
others reporting neuronal localization of OCT3 [9, 12, 26, 28]. We
also found OCT3 in DA-negative (eGFP−) and VMAT2-negative
cells. This ﬁnding is in agreement with reports indicating non-
neuronal expression of OCT3 [4, 27]. Thus, OCT3 might play a dual
role in neuronal recycling and non-neuronal breakdown of DA in
Fig. 4 Amphetamine-induced efﬂux via OCT3. a Cartoon depicting experimental paradigm used for panels b–f. Under control conditions,
microsuperfused ASP+ accumulates in YFPhOCT3 HEK293 cells leading to an increase in relative ﬂuorescent units (RFUs) with time. Inhibitors
of OCT3 block this accumulation. b Uptake of ASP+ in YFPhOCT3-expressing cells and parental HEK293 cells. Data are shown as mean ± S.E.M.,
n= 6–10 recordings per cell line. c Addition of MPP+ concentration-dependently inhibited uptake of ASP+ (arrows indicate the addition of
ASP+ and MPP+). Shown are representative traces for each condition. For analysis, the area under the curve was calculated for each trace after
the ﬁrst 60 s. *P < 0.05, Kruskal–Wallis, followed by Dunn’s (d). e No detectable difference in ASP+ uptake upon addition of AMPH (40 µM) and
cocaine (COC, 100 µM). Corticosterone (CORT, 10 µM) fully inhibited ASP+ uptake. Addition of ASP+ and the substance of interest (S.O.I.) is
indicated by arrows. Shown are representative traces for each condition. For analysis, the area under the curve was calculated for each trace
after the ﬁrst 60 s. *P < 0.05, Kruskal–Wallis, followed by Dunn’s (f). g AMPH-induced efﬂux of pre-loaded [3H]MPP+ from YFPhOCT3 cells
transiently transfected with hVMAT2 vs. vehicle-treated control. Addition of AMPH at t= 0min is indicated by the black bar; Data are mean ±
S.E.M., n= 9–12 independent observations, * indicates difference vs. control (*P < 0.05, Bonferroni’s)
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glial cells. This notion is further supported by recent electron
microscopy studies revealing the presence of OCT3 on both
neurons and glia in basolateral amygdala [34]. Taken together
with results reported herein, these ﬁndings also raise the
possibility that amphetamine might have previously unsuspected
actions in non-neuronal cells.
Having conﬁrmed the presence of OCT3 in DA neurons, we
sought to examine the functional relevance of OCT3 for actions of
amphetamine. Our ﬁrst approach was to investigate the
consequences of pharmacological inhibition of OCT3 on
amphetamine-induced locomotion and DA release in vivo. To
this end, we used D22, currently the best available blocker of
OCT3, which, unlike corticosterone, lacks activity at glucocorticoid
receptors. However, because D22 also inhibits OCT1, OCT2, and
PMAT, we carried out these studies in both OCT3+/+ and
OCT3−/− mice. D22 attenuated amphetamine-induced
locomotion and DA release in OCT3+/+ mice, an effect that
was lost in OCT3−/− mice. Moreover, D22 appeared to enhance
(P= 0.058) the ability of cocaine to suppress amphetamine
evoked DA release in OCT3+/+ mice, but not in OCT3−/− mice.
Notably, compared to vehicle treated control OCT3+/+ mice, the
combination of D22 and cocaine produced the most robust
inhibition of amphetamine-evoked DA release (P < 0.0001)
compared to either D22 (P < 0.001) or cocaine (P< 0.05).
Our behavioral data are consistent with those of Vialou and
co-workers [12] who also found no difference in basal locomotor
activity between OCT3 genotypes or in hyperlocomotion following
3.0 mg/kg amphetamine. However, Vialou et al. [12] reported that
a higher dose (10 mg/kg) that did not increase locomotion in
OCT+/+ mice (due to the emergence of stereotyped behaviors)
did so in OCT3−/− mice. This suggests that the descending limb
of amphetamine’s dose–response curve to increase locomotion
was shifted to the right in OCT3−/− mice compared with
OCT3+/+mice (i.e., OCT3−/−mice are less sensitive to the effects
of amphetamine), consistent with a role for OCT3 in the locomotor
effects of amphetamine. Our results do not provide evidence of
such a shift: 10 mg/kg did not increase locomotion, neither in
OCT3+/+ nor in OCT3−/− mice, during the time of the session
when amphetamine-induced locomotion was maximal
(Supplementary Figure S1 B–D). Differing conditions for the
locomotor assays used between our study and that of Vialou
and coworkers (2008) likely account for the differing results.
Regardless, the absence of effect of D22 on amphetamine-
induced locomotion in OCT3−/−mice provides strong support for
a role of OCT3 in actions of amphetamine.
Our results are consistent with reports that OCT3−/− mice do
not differ in basal locomotor activity or show any overt behavioral
phenotype [12, 35]. Keeping in mind that OCT3 is a low-afﬁnity,
high-capacity transporter for DA (and other monoamines), this is
not a surprising result. For example, if DAT, the high-afﬁnity, low-
capacity transporter for DA, remains functionally unimpaired, as
our results suggest, it is reasonable to expect no or very subtle
phenotypes in OCT3−/− mice (as previously reported [12, 35]).
The possibility remains that compensation in other monoamine
transporters, including D22-sensitive transporters (e.g., OCT1, 2
and PMAT), might also contribute to the lack of an overt
behavioral phenotype; however, we think this is unlikely based
on constitutive PMAT−/− mice showing no changes in the
expression of DAT, SERT, NET, or of OCT1, OCT2, or OCT3 [36]. That
PMAT expression, like OCT3, is especially rich in brain adds further
support to this contention. Moreover, our ﬁnding that the effects
of D22 to inhibit amphetamine-induced locomotion and DA
release were lost in OCT3−/− mice strongly suggests that these
actions of D22 are not mediated via OCT1, OCT2, or PMAT. That
OCT3+/+ and OCT3−/− mice show similar responses to
amphetamine-induced locomotion and DA release, with a role
for OCT3 only being revealed by treatment with D22, is therefore
also not surprising (i.e., because OCT3−/− mice have a full
complement of the high-afﬁnity DAT). The exciting implication of
our ﬁndings is that OCT3-dependent actions of amphetamine may
provide a mechanistic basis for why DAT, SERT, and NET based
therapeutics for amphetamine addiction have not been successful
[2]. That is, OCT3-dependent actions of amphetamine may only
become apparent when “uptake-1” transporters (DAT, NET, and/or
SERT) are inhibited, and/or, when OCT3 is pharmacologically
blocked. It is also worth noting that the pharmacokinetics and
disposition of amphetamine do not differ between genotypes [18],
which could also contribute to the lack of difference between
genotypes in their locomotor response to systemically delivered
amphetamine.
The unsurprising lack of any overt phenotype resulting
from constitutively knocking out a low-afﬁnity, high-capacity
transporter, is further underscored by the dramatic phenotype
resulting from knockout of the high-afﬁnity, low-capacity, DAT.
DAT−/− mice are hyperactive and show dampened or no
response to DAT targeting drugs. However, consistent with our
ﬁndings, amphetamine is not without effect in DAT knockout
mice. Though the ﬁrst characterization of these mice suggested
that DAT knockout mice were insensitive to amphetamine [37],
subsequent studies have shown that amphetamine does increase
extracellular DA in DAT knockout mice [38], even though DA
content in neurons of these mice is reduced 20-fold compared to
wild-type mice (i.e., DAT knockout mice have less than 10% of
total tissue DA [39]). In addition, the ability of amphetamine to
inﬂuence electrically evoked DA release in ex vivo nucleus
accumbens slice preparations has been reported to be both DAT
dependent and DAT independent, supporting the notion that
other mechanisms are at play [32]. These DAT-independent
mechanisms are likely many (and may include SERT, NET, and/or
receptors that regulate DA release), however, our data suggest
that OCT3 may be one such mechanism. Regardless of potential
compensation in other systems in OCT3−/−mice, our ﬁnding that
the ability of D22 to inhibit amphetamine-induced locomotion
and DA release is lost in OCT3−/− mice provides strong support
for a role of OCT3 in the action of amphetamine.
Given that D22 was without effect in OCT3−/− mice, the most
straightforward interpretation of the ability of D22 to suppress
amphetamine-evoked DA release, and to enhance the ability of
Fig. 5 Model for OCT3-dependent amphetamine-evoked DA
release. Cartoon depicting proposed mechanisms of action of
amphetamine based on present results. Amphetamine enters
neurons via DAT or diffusion across the plasma membrane “A”. Once
inside, amphetamine causes release of DA via reverse transport
through DAT “B” and OCT3 “C”
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cocaine to do so in OCT3+/+ mice, is that D22 simply prevents
efﬂux of DA via OCT3 by blocking this transporter. This
interpretation is supported by studies suggesting that D22 is an
antagonist at OCT3 [14, 40]. However, there is some evidence that
D22 may accumulate into astrocytes via an OCT3 dependent
mechanism [41], although this ﬁnding awaits further experimental
veriﬁcation. Hence, we cannot rule out the possibility that D22
may gain entry into DA neurons via OCT3 where it may interact
with intracellular components, which in turn could interact with
mechanisms that support amphetamine-induced DA efﬂux via
OCT3-dependent, or non-OCT3-dependent mechanisms. Our
results in OCT3−/− mice do not allow us to rule out this
possibility. However, our ﬁnding that D22 augments the ability of
cocaine to inhibit DA efﬂux in OCT3+/+ mice argues that, even if
D22 is a substrate for OCT3, it is not driving some facet of
signaling needed to support DAT-mediated DA release.
In terms of our in vivo chronoamperometry studies, it is also
important to note that the concentration of amphetamine (400
μM) loaded into the micropipette, was selected so as to yield
concentrations at the recording electrode of approximately 2–40
μM, taking into account well-documented dilution effects due to
diffusion through extracellular space [23]. Previous studies have
shown that this concentration range is consistent with those
reported in brain after systemic administration of a behaviorally
effective dose of amphetamine and its derivatives [31, 42]. Thus,
the concentrations of amphetamine used our in vivo efﬂux
experiments are behaviorally relevant and not supra-physiological.
Our in vivo ﬁndings are further supported by functional ex vivo
studies performed in SCG cultures, which are rich in NET and OCT3
[26]. As expected, there was marked efﬂux of pre-loaded [3H]MPP+
following addition of amphetamine. However, addition of cocaine
at a concentration that fully inhibits NET in cell-based systems
failed to fully ablate the effect of amphetamine to induce [3H]
MPP+ release from SCG cells. These data are consistent with our
in vivo data and suggest that amphetamine-evoked [3H]MPP+
efﬂux occurs through mechanisms other than NET in SGCs. We
found that full inhibition of amphetamine-evoked [3H]MPP+
release could only be accomplished if both OCT3 and NET were
fully inhibited (i.e., by D22 and cocaine, respectively). Thus,
cocaine may fully attenuate amphetamine-induced efﬂux of [3H]
MPP+ via its action at NET (as well as DAT and SERT) (see Fig. 3
and [43, 44]) in cell-based expression systems, but in an ex vivo
SCG cell preparation this inhibition is not complete. SCGs are rich
in NET and OCT3, and devoid of OCT1 and OCT2 [26], supporting a
role for OCT3 in the action of D22 to inhibit substrate efﬂux. It is
unknown if PMAT is expressed in SCGs; however, our ﬁnding that
corticosterone (which blocks OCT3 but not PMAT) recapitulated
the effect of D22 to inhibit amphetamine-evoked [3H]MPP+
release in SCGs provides strong evidence that this effect of D22 is
OCT3 dependent.
After replicating the well-established ﬁnding that cocaine does
not affect OCT3-mediated transport [14], we found that D22 (OCT/
PMAT inhibitor) enhances the ability of cocaine (DAT/NET/SERT
blocker) to inhibit amphetamine-evoked substrate (DA, [3H]MPP+)
release, both in vivo and ex vivo. Remarkably, however, we
found that amphetamine does so in a manner that does not
involve its transport into the cell via OCT3. Behaviorally relevant
concentrations of amphetamine did not inhibit uptake of
ASP+ into YFPhOCT3 expressing HEK293 cells, suggesting that
amphetamine is not a substrate for OCT3, or at best, only a poor
substrate at very high (supra-behaviorally relevant) concentra-
tions. These ﬁndings, together with evidence that amphetamine
can gain entry to cells via active transport [45] or diffusion across
the plasma membrane [46–48], highlights access to cytosolic
monoamines as a key element for OCT3 to contribute to the
actions of amphetamine. Given that an important part of the
mechanism of action of amphetamine is its activity at VMAT2,
which results in release of monoamines from vesicular stores into
the cytosol [17, 49], this notion is further supported by our data
showing that amphetamine was able to evoke robust efﬂux
of [3H]MPP+ in YFPhOCT3 cells co-transfected with hVMAT2.
Interestingly, Freyberg et al. [49] reported that the effects of
methamphetamine on locomotion were drastically reduced by
acute treatment with a VMAT2 inhibitor, whereas the effects of
cocaine were not affected. This ﬁnding supports the idea that the
effects of amphetamine-related drugs at VMAT2 are essential to
their action [49]. Perturbed VMAT2 function and concomitant
elevations in cytosolic monoamines results in a gradient that
favors outward transport (efﬂux). Since the electrochemical
gradient of substrate provides the driving force for
OCT3-mediated transport, our data are in accord with the notion
that OCT3-dependent amphetamine-induced monoamine release
is due to access of OCT3 to high concentrations of cytosolic
monoamines. It is important to mention that earlier studies
demonstrated that amphetamine induces release of monoamines
that are derived from a “newly synthesized” pool in vivo [50].
Consistent with this observation, amphetamine was found to
induce efﬂux of DA when vesicular stores were depleted
with reserpine [51, 52]. Contrasting ﬁndings have been reported
by Florin and colleagues, showing that in vivo effects of
amphetamine are sensitive to reserpine [53]. Additionally,
Freyberg et al. demonstrated that locomotion stimulated with
methamphetamine and amphetamine was sensitive towards a
VMAT inhibitor in a dose-dependent manner [49]. This assembly of
pharmacological evidence indicates that alternative intracellular
effects of amphetamine may contribute to OCT3-mediated reverse
transport in vivo, ranging from inhibition of monoamine oxidases
to activation of kinases and alterations of the transciptome
[17, 54].
Taken together, our data support the working model depicted
in Fig. 5. Amphetamine enters neurons via DAT (NET or SERT) or
diffusion across the plasma membrane or perhaps even gaining
entry into DA neurons via an as yet unknown mechanism (e.g.,
[55]). That amphetamine may gain entry by diffusion or via yet
unknown mechanisms is supported by our ﬁnding that (1)
pre-treatment of SCG neurons with cocaine at a concentration
that fully blocks high-afﬁnity monoamine transporters in cell
systems failed to fully block amphetamine-evoked release of [3H]
MPP+ in cultured neurons, and (2) amphetamine is, at best, a poor
substrate for OCT3. Once inside the neuron, amphetamine
reverses VMAT activity, causing release of DA into the cytosol
and subsequent release of DA via reverse transport through DAT
and OCT3. It must be kept in mind, however, that in addition to
the intraneuronal effects of amphetamine discussed above, non-
neuronal OCT3 might also contribute to the overall actions of
amphetamine, through currently unknown mechanisms (if at all).
It is possible that OCT3 and DAT may need to physically interact in
order for amphetamine to promote efﬂux via OCT3. These will be
important areas for future research.
In sum, our results reveal OCT3 as an important player in the
actions of amphetamine. Current treatments for addiction to
amphetamine and amphetamine-type psychostimulants targeting
only the high-afﬁnity transporters DAT, NET, and SERT are far from
being satisfactory. Our results introduce OCT3 as a potential new
target for the development of novel therapeutics to treat addiction
to amphetamine and its congeners. Together, these ﬁndings nourish
the ﬁeld of psychostimulant research by pointing to OCT3 as an
important player in harmonizing monoaminergic signaling.
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